Waystar Considers Sale Amid Market Challenges, Sources Reveal
Healthcare software provider Waystar is exploring a potential sale, just two years after its public listing.
Waystar, a prominent healthcare software company, is reportedly exploring strategic options, including a potential sale, according to sources familiar with the matter. This move comes just two years after the company's initial public offering on the New York Stock Exchange.
Investment Bank Evercore Engaged
Based in Lehi, Utah, and Louisville, Kentucky, Waystar has engaged investment bank Evercore to advise on the exploratory process, sources revealed. The discussions are said to be in the preliminary stages, and while the possibility of a sale is being considered, no final decision has been made. Both Waystar and Evercore have declined to comment on the matter.
Market Valuation and Investor Sentiment
Waystar's market valuation has been affected by a broader downturn in the software sector, with its share price decreasing by 24% this year, bringing its market value to approximately $4.8 billion. The company had initially positioned itself as a technology-focused entity, automating healthcare administrative tasks to achieve higher valuations typical of tech firms. While this strategy initially attracted investors, the stock has faced pressure amid concerns about potential disruptions from advancements in artificial intelligence.
Company Background and Ownership
Waystar was created through the 2017 merger of Zirmed and Navicure, both involved in healthcare revenue management. The company went public in 2024, backed by significant investors including EQT, the Canada Pension Plan Investment Board (CPPIB), and Bain Capital. Currently, EQT holds the largest stake at 13%, followed by CPPIB with 10%, and BlackRock Institutional Trust Company with 8%, as per data from LSEG.
EQT and BlackRock have declined to comment on the potential sale, while CPPIB did not immediately respond to requests for comment.
Potential Market Implications
The exploration of a sale could test investor appetite for software companies amid a challenging market environment. Analysts have noted that investor interest in software firms has waned due to fears of technological disruptions, impacting valuations across the sector.
Waystar's exploration of strategic options highlights the ongoing adjustments within the healthcare technology sector as companies navigate evolving market conditions and investor expectations.